Audit: QRS - Squalene for Skin Rejuvenation

Audit conducted on 14/09/2026 10:30 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol values (ER Therapeutic Protocol), time-to-effect values (ER Practical Considerations, “Time to effect”), benefit/risk items (ER tier headings), gate items (ER Key Interactions & Contraindications), monitoring rows and cadence (ER Monitoring Protocol & Defining Success).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target; track change from the individual’s own baseline” carried verbatim for marker_4 and marker_5; at-a-glance preserves “has never been compared against a blank cream”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Route qualifiers retained where they carry the claim (“with high-dose oral squalene”, “shark liver oil-sourced oral squalene”); no directional change detected.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid Squalene” list; Key Interactions only from the ER interaction bullets; no modifying factors surfaced as gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no author names and no brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present; the ER’s “Examine cites” attribution in the oral-dose bullet was dropped rather than restated.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-first register matching the ER; the ER’s own hedges about isolated squalane are preserved.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified protocol and monitoring targets alongside plain-language explanation of what each measure shows.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Applied to damp skin…”, “Applying after the day’s ultraviolet and ozone exposure has ended limits peroxide formation”).
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions; no “should”, “recommend”, or “advise” anywhere in the body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Gate items are bare noun phrases; protocol cells state the regimen rather than instructing.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain-language forms used throughout (“water loss through the skin”, “small white cysts”, “outer-layer water content”); the technical biomarker names are the ER’s own verbatim table labels.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is a single clause; no sub-line exceeds two lines of text.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” occurrences.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Instrumental sebum, transepidermal water loss and corneometry targets assume a proactive, measurement-driven reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring cadence includes research-grade instrumental skin measurements and serum panels.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes willingness to pursue cosmetic-science instrumentation and repeated laboratory testing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance foregrounds the evidence gap for topical squalane and the tolerability cost of the oral route rather than a generic “safe moisturizer” framing.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; “rejuvenation” is used in the title only, as the ER’s canonical topic.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route is given as “ingested”/”oral”/”topical”/”applied”; “gastrointestinal upset”, “contact sensitization”, “follicular occlusion” used in place of colloquial equivalents.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings byte-identical to the template (lines 445, 491, 541, 566, 578, 598, 627, 631–633, 750); tier labels “Medium”, “Low”, “Speculative” unchanged, High tier hidden per 12.5/13.5.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# placeholders are expanded to marker_1–7 and qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff against the template shows changes confined to the metadata block and the content of checklist-governed spans; CSS, structure, website= spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the empty High benefit/risk tiers are governed by items 12.5 and 13.5, which mandate hiding rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard topical regimen”, “Best time of day”, “Alternative — oral squalene” are verbatim ER Therapeutic Protocol bold labels; monitoring row labels are verbatim ER biomarker-table entries.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol, marker and qualitative labels are taken verbatim; the three time-to-effect labels use the ER’s own wording from the “Time to effect” bullet, which carries no per-aspect bold label.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points present; the ER’s ⚠️ Conflicted and ⭕️ markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every item reduced to a single clause with magnitudes, mechanisms and citations stripped; the item counts that remain (7 markers, 8 interactions, 6 qualitative markers) are mandated by items 14.2, 9.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment opens at line 2, immediately after <!doctype html> at line 1, and closes at line 14 before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding descriptive line is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element echoes the block.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because the value contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: squalene_skin_2026-0914-0745_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0914-1024, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname plus version number, no qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: squalene_skin_2026-0914-0745_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-2 and git_issue: 6210; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Squalene for Skin Rejuvenation - Quick Reference Sheet”; ER canonical_topic is “Squalene for Skin Rejuvenation”; no characters require entity encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Squalene for Skin Rejuvenation”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/14/2026”, correctly derived from qrs_creation_date: 2026-0914-1024.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is byte-identical to the template apart from the three governed spans; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion’s three load-bearing points: squalane is the stabilized form actually used, the only controlled human evidence is oral, and the applied oil has never been isolated against a vehicle.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a separate ER Conclusion sentence (light well-tolerated oil that slows water loss; single controlled study in older women with smoother skin at very high doses plus loose stool and darkening of facial pigment; no controlled comparison against a blank cream).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “an oil the skin already makes”, “loose stool”, “darker facial pigment”, “blank cream” are all non-specialist terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “a controlled human study” with no name, year, or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items trace to the “Populations who should avoid Squalene” list inside that ER section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-population bullets are represented, one-to-one, with none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 569–573: five well-formed <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic tails stripped (e.g., ER’s “…for whom occlusive facial oils add pore-blocking substrate…” and “…because preformed retinol above 3,000 micrograms daily carries a risk of birth defects” both removed); no dash-introduced clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Investigator Global Assessment grade 4”, “less than 48 hours old”, “in active flare”, “oral squalene at gram-level doses”, “shark liver oil-sourced oral squalene” and “shark-sourced material” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five such populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to the bulleted interaction list at the head of that ER section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets carried; none of them duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 581–588: eight well-formed <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item reduced to the agent name plus its parenthetical; the ER’s “Caution”/”Monitor” labels, mechanisms and “Mitigation:” sentences are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained verbatim: “(tretinoin, adapalene, tazarotene)”, “(glycolic, lactic)”, “(over-the-counter)”, “(oral)”, “(vitamin E, astaxanthin, carotenoids)”, “(atorvastatin, rosuvastatin, simvastatin)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses; all parentheticals are already plain comma-separated lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to bullets in the ER Therapeutic Protocol section (lines 310, 312, 314).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The standard topical regimen, the timing that controls the ER’s principal risk (oxidation), and the oral alternative with its dose distinction are the three decision-bearing aspects; the remaining bullets are modifiers or background.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects and all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Labels verbatim from ER bold labels; values “2–4 drops, 100% plant-derived squalane”, “Evening”, “300 mg daily” and all three sub-lines trace directly to ER lines 310, 312 and 314.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet names exactly three horizons — surface softening, water-loss improvement, fine-line appearance — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Fine-line appearance first (tied to the Medium-tier wrinkle-depth benefit), then the two horizons tied to the Low-tier lipid-replacement and softening benefit.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct aspects and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values “8–12 weeks”, “2–4 weeks”, “Within hours” match the ER verbatim; sub-lines combine the ER’s own wording with the repeat-measurement points from the ER Monitoring Protocol & Defining Success narrative.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed item corresponds to a sub-heading under ER Expected Benefits.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 543, 544, 550 and 553.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading; all “Magnitude:” text, dose figures, PMID links and study descriptions are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the Benefits card.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No benefit reaches High”; line 543 correctly carries style="display: none" with no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All ten listed items correspond to sub-headings under that ER section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 600, 601, 608 and 616.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading; incidence figures (35%/55%), the 10 mM peroxide detail, the 12% cholesterol rise and all citations are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the Risks card.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”; line 600 correctly carries style="display: none" with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows come from the biomarker table in ER Monitoring Protocol & Defining Success (ER lines 368–376).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER biomarkers present with names, targets and rationales carried verbatim: sebum output, transepidermal water loss, outer-layer water content, skin surface squalene peroxide, serum squalene, serum lipid panel, serum retinol.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 740–744 reproduce the ER cadence: baseline, instrumental measurements at 4 and 12 weeks then every 6 months, weekly bowel habit for the first month on oral use, serum lipids and retinol at 3 months then annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the subjective-marker list in ER Monitoring Protocol & Defining Success (ER lines 380–385).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER subjective markers present and verbatim, none omitted or added.

Issues 14/09/2026 10:30

Pass rate 100.00%. No issues found.